Drug Landscape ›
Zolgensma ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 2,672
Most-reported reactions
Pyrexia — 523 reports (19.57%) Vomiting — 489 reports (18.3%) Aspartate Aminotransferase Increased — 340 reports (12.72%) Alanine Aminotransferase Increased — 306 reports (11.45%) Hepatic Enzyme Increased — 260 reports (9.73%) Thrombocytopenia — 188 reports (7.04%) Platelet Count Decreased — 164 reports (6.14%) Liver Function Test Increased — 142 reports (5.31%) Pneumonia — 132 reports (4.94%) Troponin I Increased — 128 reports (4.79%)
Source database →
Zolgensma in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Zolgensma approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Zolgensma in United States?
Novartis Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.